In gastric cancer cells, CDK12 phosphorylates PAK2 for activation of the MAPK signaling, and its specific inhibitor Proterol has been approved for clinical trials by the FDA due to positive outcomes obtained from PDX and cell line studies [234]. The gene discussed is PAK2; the disease is gastric cancer.